Search

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

EHA congratulates the Spanish Society of Hematology on its 60th anniversary

EHA President, John Gribben and member of the SEHH, María Victoria Mateos

On Thursday, June 20 the Spanish Society of Hematology (SEHH) officially celebrated its 60th anniversary with a commemorative event in Madrid.

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more

EHA-SWG Scientific Meeting on Patient-centered Geriatric Hematology - report

Live sessions: October 6-7, 2021

Chairs: Prof R Cordoba (Spain) and Dr V Goede (Germany)

An international group of hematologists, specialist nurses, patient advocates, geriatricians, basic research, and pharma representatives gathered digitally to participate in this meeting.

Read more

EHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects of the disease!

Live days: April 29-30, 2021

Content available: April 22, 2021 – May 29, 2021

Chair: Prof Dr C Dufour

Junior and senior hematologists from all over the world gathered on April 29-30, 2021 for the live days of the EHA-SWG Scientific Meeting on…

Read more

From Plans to Action: European Cancer Summit

From Plans to Action:  European Cancer Summit (Brussels-Hybrid, November 17-18, 2021) 
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more